Coronary Artery Anomaly (CHD)

Categories: Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Coronary Artery Anomaly

MalaCards integrated aliases for Coronary Artery Anomaly:

Name: Coronary Artery Anomaly 12 15 37
Coronary Artery Disease 12 43 15 71
Myocardial Ischemia 43 17 71
Coronary Artery Disease, Susceptibility to 29 6
Coronary Arteriosclerosis 12 71
Coronary Heart Disease 12 71
Coronary Disease 12 43
Congenital Anomaly of Coronary Artery 12
Coronary Artery Anomaly, Congenital 12
Coronary Artery Abnormality 12
Coronary Syndrome 15
Chd 12


External Ids:

Disease Ontology 12 DOID:11843 DOID:3393
UMLS 71 C0010054 C0010068 C0151744 more

Summaries for Coronary Artery Anomaly

MalaCards based summary : Coronary Artery Anomaly, also known as coronary artery disease, is related to hyperlipidemia, familial combined, 3 and familial hypercholesterolemia, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Coronary Artery Anomaly is PON1 (Paraoxonase 1), and among its related pathways/superpathways are Dilated cardiomyopathy (DCM) and Folate Metabolism. The drugs Estradiol and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Coronary Artery Anomaly

Diseases in the Coronary Artery Anomaly family:

Coronary Artery Disease, Autosomal Dominant, 1 Coronary Artery Disease, Autosomal Dominant 2

Diseases related to Coronary Artery Anomaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1393)
# Related Disease Score Top Affiliating Genes
1 hyperlipidemia, familial combined, 3 33.7 PON1 COG2 APOB APOA1
2 familial hypercholesterolemia 33.6 PON1 NOS3 CRP COG2 APOB APOA1
3 retinal vascular occlusion 33.1 PLG EDN1 CRP
4 lipid metabolism disorder 32.7 PON1 IRS1 CRP COG2 APOB APOA1
5 vascular disease 32.3 PON1 PLG NPPB NOS3 MIR145 KNG1
6 glucose intolerance 32.2 NOS3 IRS1 CRP APOB APOA1 ALB
7 peripheral vascular disease 32.1 NOS3 KNG1 CRP COG2 APOB APOA1
8 homocysteinemia 32.1 PON1 NOS3 CRP ALB
9 arteriosclerosis 32.1 PON1 NOS3 EDN1 CRP COG2 APOB
10 diabetes mellitus, noninsulin-dependent 32.1 PON1 PLG NOS3 MIR483 MB IRS1
11 chronic kidney disease 32.0 TNNT2 TNNI3 PON1 NPPB NOS3 EDN1
12 diabetes mellitus 32.0 PON1 NPPB NOS3 MIR145 KNG1 IRS1
13 fatty liver disease 32.0 IRS1 CRP APOB ALB
14 kidney disease 32.0 TNNT2 PON1 NPPB NOS3 EDN1 CRP
15 sleep apnea 32.0 NPPB NOS3 EDN1 CRP APOB ALB
16 hyperglycemia 32.0 NOS3 IRS1 APOB ALB
17 impotence 32.0 NOS3 KNG1 EDN1 ACE
18 hypothyroidism 31.9 PON1 CRP COG2 APOB APOA1 ALB
19 body mass index quantitative trait locus 11 31.9 PON1 PLG NOS3 MIR483 KNG1 IRS1
20 peripheral artery disease 31.9 NPPB NOS3 EDN1 CRP APOB APOA1
21 pulmonary disease, chronic obstructive 31.9 NPPB MB CRP ALB ACE
22 non-alcoholic fatty liver disease 31.9 IRS1 CRP APOB APOA1 ALB
23 atrial fibrillation 31.9 TNNT2 TNNI3 NPPB NOS3 CRP ALB
24 tetralogy of fallot 31.9 TNNT2 TNNI3 NPPB EDN1 CRP ACE
25 proteasome-associated autoinflammatory syndrome 1 31.9 IL1RN CRP ALB
26 mitral valve insufficiency 31.8 TNNT2 TNNI3 NPPB CRP ALB ACE
27 hyperuricemia 31.8 CRP APOB ALB
28 hypertension, essential 31.8 TNNT2 TNNI3 PON1 PLG NPPB NOS3
29 end stage renal failure 31.8 NPPB IL1RN CRP COG2 APOB ALB
30 microvascular complications of diabetes 5 31.7 PON1 PLG NOS3 ALB ACE
31 cardiovascular system disease 31.7 PON1 PLG NPPB NOS3 MIR145 MB
32 cardiac arrest 31.7 TNNT2 NPPB KNG1 ALB ACE
33 carotid stenosis 31.7 NOS3 CRP ACE
34 familial hyperlipidemia 31.7 PON1 CRP COG2 APOB APOA1 ACE
35 intermittent claudication 31.7 TNNT2 CRP ALB ACE
36 anterolateral myocardial infarction 31.6 NPPB ACE
37 osteoporosis 31.6 NPPB NOS3 IRS1 IL1RN EDN1 CRP
38 dilated cardiomyopathy 31.6 TNNT2 TNNI3 NPPB NOS3 MB KNG1
39 pericardial effusion 31.6 TNNI3 NPPB CRP ALB ACE
40 heart valve disease 31.6 TNNT2 TNNI3 NPPB EDN1 CRP ALB
41 ischemia 31.5 PON1 NPPB NOS3 MB KNG1 IL1RN
42 kawasaki disease 31.5 NPPB MIR145 CRP ALB
43 migraine with or without aura 1 31.5 PLG NOS3 KNG1 EDN1 CRP ALB
44 constrictive pericarditis 31.5 TNNI3 NPPB IL1RN CRP ALB ACE
45 angina pectoris 31.5 TNNI3 NPPB NOS3 MB KNG1 EDN1
46 tangier disease 31.5 APOB APOA1 ALB
47 generalized atherosclerosis 31.5 CRP COG2 APOB ALB ACE
48 sexual disorder 31.5 NOS3 EDN1 ALB ACE
49 congestive heart failure 31.5 TNNT2 TNNI3 NPPB NOS3 KNG1 EDN1
50 coronary artery vasospasm 31.5 TNNI3 NOS3 KNG1 EDN1 CRP ACE

Graphical network of the top 20 diseases related to Coronary Artery Anomaly:

Diseases related to Coronary Artery Anomaly

Symptoms & Phenotypes for Coronary Artery Anomaly

UMLS symptoms related to Coronary Artery Anomaly:

tremor, angina pectoris, edema, chest pain, equilibration disorder, other and unspecified angina pectoris, substernal pain

MGI Mouse Phenotypes related to Coronary Artery Anomaly:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ACE ALB APOA1 APOB CRP EDN1
2 homeostasis/metabolism MP:0005376 9.8 ACE ALB APOA1 APOB COG2 CRP
3 muscle MP:0005369 9.23 ALB APOB EDN1 IRS1 MB NOS3

Drugs & Therapeutics for Coronary Artery Anomaly

Drugs for Coronary Artery Anomaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 981)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
Coal tar Approved Phase 4 8007-45-2
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
Zolpidem Approved Phase 4 82626-48-0 5732
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
15 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Gliclazide Approved Phase 4 21187-98-4 3475
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
Pravastatin Approved Phase 4 81093-37-0 54687
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
Probucol Approved, Investigational Phase 4 23288-49-5 4912
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
Digoxin Approved Phase 4 20830-75-5 30322 2724385
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
29 Nutmeg Approved Phase 4
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Famotidine Approved Phase 4 76824-35-6 3325
Eplerenone Approved Phase 4 107724-20-9 150310 443872
Sodium citrate Approved, Investigational Phase 4 68-04-2
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Etomidate Approved Phase 4 33125-97-2 36339 667484
Glyburide Approved Phase 4 10238-21-8 3488
Linagliptin Approved Phase 4 668270-12-0 10096344
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Trandolapril Approved Phase 4 87679-37-6 5484727
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Cosyntropin Approved Phase 4 16960-16-0 16129617
Fondaparinux Approved, Investigational Phase 4 104993-28-4
Citalopram Approved Phase 4 59729-33-8 2771

Interventional clinical trials:

(show top 50) (show all 7733)
# Name Status NCT ID Phase Drugs
1 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
2 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
4 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
5 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
6 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
7 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
8 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
9 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
10 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
11 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
12 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
13 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
14 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
15 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
16 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
17 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
19 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
20 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
21 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
22 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
23 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
24 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
25 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
26 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
27 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
28 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
29 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
30 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
31 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
32 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
33 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
34 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
35 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
36 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
37 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
38 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
39 Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
40 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
41 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
42 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
43 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
44 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
45 Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
46 Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study - Unknown status NCT01453712 Phase 4
47 The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) Unknown status NCT01903902 Phase 4
48 Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns After Sirolimus-eluting Stent Implantation Assessment by Optical Coherence Tomography Unknown status NCT01024179 Phase 4
49 Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V Unknown status NCT00714545 Phase 4
50 The ABC Trial - Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery Unknown status NCT01623193 Phase 4

Search NIH Clinical Center for Coronary Artery Anomaly

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Atorvastatin calcium
Cerivastatin sodium
Cholestyramine Resin
Colesevelam hydrochloride
Colestipol Hydrochloride
Dextrothyroxine Sodium
Fish Liver Oils
Fluvastatin sodium
Isosorbide Dinitrate
Isosorbide Mononitrate
Pravastatin Sodium

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Coronary Artery Anomaly cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Coronary Artery Anomaly:
CD34+ stem cells for treatment of congestive heart failure
Embryonic/Adult Cultured Cells Related to Coronary Artery Anomaly:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120

Cochrane evidence based reviews: coronary artery disease

Genetic Tests for Coronary Artery Anomaly

Genetic tests related to Coronary Artery Anomaly:

# Genetic test Affiliating Genes
1 Coronary Artery Disease, Susceptibility to 29

Anatomical Context for Coronary Artery Anomaly

MalaCards organs/tissues related to Coronary Artery Anomaly:

Heart, Endothelial, Testes, Kidney, Bone, Liver, Lung

Publications for Coronary Artery Anomaly

Articles related to Coronary Artery Anomaly:

(show top 50) (show all 30992)
# Title Authors PMID Year
Coronary artery disease and a functional polymorphism of hTERT. 61 6
16890917 2006
A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. 61 6
10591678 1999
The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. 61 6
8770857 1996
A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. 61 6
8675673 1995
Paraoxonase-1 is a major determinant of clopidogrel efficacy. 6
21170047 2011
Paraoxonase 1 polymorphisms and survival. 6
15241482 2004
Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. 6
15240653 2004
G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. 6
14707024 2004
Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. 6
14671192 2003
The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. 6
12843189 2003
Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. 6
12082503 2002
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 6
11918623 2002
Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. 6
11888590 2002
Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. 6
11889198 2002
LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. 6
11788650 2002
Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. 6
11810302 2002
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. 6
11335891 2001
The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. 6
11238489 2001
The Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. 6
10843189 2000
The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. 6
10430617 1999
Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study. 6
10084586 1999
A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. 6
9661650 1998
Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? 6
9443884 1998
The Arg192 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese. 6
9385372 1997
Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. 6
9215303 1997
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. 6
9011577 1997
A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. 6
8647950 1996
Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. 6
7623569 1995
Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. 6
8104271 1993
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. 6
7916578 1993
The molecular basis of the human serum paraoxonase activity polymorphism. 6
8098250 1993
Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. 6
1311924 1992
Genetic engineering with endothelial nitric oxide synthase improves functional properties of endothelial progenitor cells from patients with coronary artery disease: an in vitro study. 54 61
19479297 2009
Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. 54 61
19778663 2009
Plasma brain natriuretic peptide at rest and after adenosine-induced myocardial ischemia in normotensive and essential hypertensive patients with suspected coronary artery disease. 54 61
18951935 2009
Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease. 54 61
18413560 2008
Influence of left ventricular filling pattern on exercise-induced changes of natriuretic peptides in patients with suspected coronary artery disease. 54 61
17442418 2008
Presence and severity of coronary artery disease and changes in B-type natriuretic peptide levels in patients with a normal systolic function. 54 61
17002921 2006
B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease. 54 61
18651043 2006
Usefulness of high-sensitivity IL-6 measurement for clinical characterization of patients with coronary artery disease. 54 61
15900566 2005
[New biological markers for acute coronary artery disease]. 54 61
14978429 2003
[Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus]. 54 61
12728597 2003
Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. 54 61
11823078 2002
Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. 54 61
11855668 2002
[Endothelin-1 in coronary artery disease]. 54 61
11770304 2001
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. 54 61
11020393 2000
Soluble L-selectin level is a marker for coronary artery disease in type 2 diabetic patients. 54 61
10587840 1999
Short-term effect of exercise on platelet factor 4 in normal subjects and in patients with coronary artery disease. 54 61
10686775 1999
Atrial natriuretic peptide attenuates pacing-induced myocardial ischemia during general anesthesia in patients with coronary artery disease. 54 61
9972741 1999
Effect of ACE inhibition on myocardial ischaemia. 54 61
9796838 1998

Variations for Coronary Artery Anomaly

ClinVar genetic disease variations for Coronary Artery Anomaly:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PON1 NM_000446.7(PON1):c.575A>G (p.Gln192Arg)SNV risk factor 13735 rs662 7:94937446-94937446 7:95308134-95308134
2 PON1 NM_000446.7(PON1):c.163T>A (p.Leu55Met)SNV risk factor 13736 rs854560 7:94946084-94946084 7:95316772-95316772
3 IRS1 NM_005544.2(IRS1):c.2911G>A (p.Gly971Arg)SNV risk factor 29761 rs1801278 2:227660544-227660544 2:226795828-226795828
4 TERT TERT, -1327T-CSNV Uncertain significance 12734

Copy number variations for Coronary Artery Anomaly from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13312 1 1 117600000 Copy number Coronary Disease
2 207742 6 160872504 161007397 Copy number LPA Coronary Disease
3 207743 6 160872504 161007397 Copy number LPA Coronary Disease
4 250037 9 19900000 32800000 Copy number Coronary Disease

Expression for Coronary Artery Anomaly

Search GEO for disease gene expression data for Coronary Artery Anomaly.

Pathways for Coronary Artery Anomaly

GO Terms for Coronary Artery Anomaly

Cellular components related to Coronary Artery Anomaly according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.09 PON1 PLG MB KNG1 IL1RN APOB
2 extracellular region GO:0005576 9.9 PON1 PLG NPPB KNG1 IL1RN EDN1
3 platelet alpha granule lumen GO:0031093 9.65 PLG KNG1 ALB
4 spherical high-density lipoprotein particle GO:0034366 9.49 PON1 APOA1
5 troponin complex GO:0005861 9.46 TNNT2 TNNI3
6 high-density lipoprotein particle GO:0034364 9.43 PON1 APOB APOA1
7 cardiac myofibril GO:0097512 9.4 TNNT2 TNNI3
8 extracellular space GO:0005615 9.4 PON1 PLG NPPB MIR150 KNG1 IL1RN
9 intermediate-density lipoprotein particle GO:0034363 9.37 APOB APOA1
10 blood microparticle GO:0072562 9.35 PON1 PLG KNG1 APOA1 ALB
11 cardiac Troponin complex GO:1990584 9.32 TNNT2 TNNI3

Biological processes related to Coronary Artery Anomaly according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.56 PLG KNG1 APOA1 ALB
2 cellular protein metabolic process GO:0044267 9.55 PLG KNG1 APOB APOA1 ALB
3 negative regulation of ATPase activity GO:0032780 9.51 TNNT2 TNNI3
4 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.49 IL1RN APOA1
5 chylomicron assembly GO:0034378 9.48 APOB APOA1
6 chylomicron remodeling GO:0034371 9.46 APOB APOA1
7 body fluid secretion GO:0007589 9.43 NPPB EDN1
8 negative regulation of hydrolase activity GO:0051346 9.4 NOS3 APOA1
9 lipoprotein biosynthetic process GO:0042158 9.37 APOB APOA1
10 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.32 NOS3 EDN1
11 regulation of blood vessel diameter GO:0097746 9.13 NPPB NOS3 ACE
12 regulation of blood pressure GO:0008217 8.92 NPPB NOS3 EDN1 ACE

Molecular functions related to Coronary Artery Anomaly according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.35 PLG NPPB KNG1 EDN1 APOA1
2 troponin C binding GO:0030172 8.62 TNNT2 TNNI3

Sources for Coronary Artery Anomaly

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....